Login to Your Account



Déjà Vu for Cancer Stem Cell Play

Stemline Therapeutics Is First Biotech IPO of 2013

By Peter Winter
BioWorld Insight Editor

Wednesday, January 30, 2013
Despite the positive reception that the Street afforded Intercept Pharmaceuticals Inc. and Kythera Biopharmaceuticals Inc., which each priced their initial public offerings (IPOs) at the top end of their ranges on the same day back in October, the bullish response to those two biotech offerings was not, it turned out to be, a harbinger for others to quickly follow suit.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription